LN229-luc Orthotopic Mouse Model Service for Brain Cancer

The LN229-luc orthotopic mouse model for brain cancer offers a highly tractable human glioblastoma xenograft platform distinguished by its diffuse, perivascular infiltration pattern and slower growth kinetics that more faithfully mirror clinical disease progression. Alfa Cytology provides a full-spectrum preclinical service for this model, spanning luciferase-stable cell line sourcing, precision stereotactic intracranial implantation, serial bioluminescence imaging, and detailed neuropathological endpoint analysis to advance your glioblastoma drug discovery and mechanism-of-action studies.

Overview of LN229-luc Orthotopic Mouse Model for Brain Cancer

The LN229-luc orthotopic brain tumor model is established by stereotactic injection of luciferase-transduced human LN229 glioblastoma cells into the striatum of immunodeficient mice, creating a human-derived xenograft that recapitulates the infiltrative growth, perivascular dissemination, and protracted disease course characteristic of patient glioblastoma. Unlike the compact, demarcated tumors formed by U87MG xenografts, LN229 tumors grow with diffuse margins, sending satellite cells along blood vessels into remote brain regions—a pattern that closely resembles the clinical challenge of complete surgical resection and explains the high recurrence rates seen in patients. The stable luciferase reporter integrated into the LN229 genome enables quantitative, noninvasive bioluminescence imaging (BLI) across the entire disease trajectory, from initial engraftment through peak tumor burden, allowing researchers to monitor tumor growth kinetics, assess therapeutic response longitudinally, and detect early metastatic or disseminated lesions with exceptional sensitivity.

Fig 1. Phase contrast and fluorescence images of U87 and LN229 cells grown in monolayers. (Han, Ji-hun, et al., 2020)

From a molecular standpoint, the LN229 cell line harbors a mutated TP53 allele alongside homozygous deletion of the p16/CDKN2A and p14ARF tumor suppressor loci, while retaining a wild-type PTEN gene—an alteration profile that places it within the classical glioblastoma subtype and renders it particularly relevant for evaluating agents targeting the p53 pathway, cell cycle checkpoints, or PI3K-AKT signaling nodes. When implanted orthotopically, LN229 cells engage with the murine brain microenvironment in a manner that preserves human tumor cell–host stroma crosstalk, including interactions with endothelial cells, microglia, and extracellular matrix components, thereby providing a more translationally faithful testing ground for chemotherapeutics, targeted small molecules, oncolytic viruses, and blood-brain barrier–penetrant delivery systems than subcutaneous or flank xenograft alternatives.

Cell Line Information: LN229-luc

The LN229-luc cell line is a human glioblastoma multiforme line engineered to stably express firefly luciferase, enabling sensitive, ATP-dependent bioluminescent detection in living animals. The parental LN229 line was originally established in 1979 from a right frontal parieto-occipital glioblastoma resected from a 60-year-old European female patient at the Neurosurgical Service of the University Hospital (CHUV) in Lausanne, Switzerland. Below is a comprehensive summary of the key characteristics of the LN229 parental and LN229-luc reporter cell lines:

Our Services

Alfa Cytology delivers a turnkey LN229-luc orthotopic glioblastoma model service engineered to meet the exacting demands of your preclinical neuro-oncology research. Our offering encompasses luciferase-stable cell line qualification, stereotactic intracranial implantation with validated coordinates, scheduled bioluminescence imaging sessions, and comprehensive histopathological and molecular endpoint characterization—ensuring reproducible, high-fidelity data that de-risks your therapeutic pipeline from early target validation through candidate selection.

Workflow of LN229-luc Orthotopic Mouse Model Construction

Construction of the LN229-luc orthotopic brain tumor model employs a refined stereotactic intracranial injection protocol optimized for consistent tumor engraftment, minimal perioperative mortality, and reliable bioluminescence signal detection. The workflow integrates surgical precision, longitudinal BLI monitoring, and rigorous endpoint analysis to generate a robust preclinical glioblastoma platform. The essential steps are outlined below:

1. Cell Preparation and Quality Control: LN229-luc cells are expanded under standard culture conditions and harvested during logarithmic growth phase. Cell viability is confirmed by trypan blue exclusion (target >95% viability), and luciferase expression is validated by in vitro luciferase assay using serial dilutions of cell lysate. Mycoplasma testing and STR authentication are performed per release criteria prior to inoculation.
2. Preoperative Preparation and Anesthesia: Female athymic nude mice or NOD-SCID mice (6–8 weeks old, ~20 g) are acclimatized for at least one week. On the day of surgery, mice are anesthetized with isoflurane (3–4% induction, 1.5–2% maintenance in medical oxygen) or an intraperitoneal ketamine/xylazine cocktail. The scalp is shaved and sterilized with alternating povidone-iodine and 70% ethanol. Body temperature is maintained on a heated surgical platform throughout the procedure.
3. Stereotactic Cranial Exposure: A midline scalp incision is made to expose the cranium, and bregma is identified as the stereotactic zero reference. A dental drill creates a burr hole at the following coordinates relative to bregma: anterior–posterior +0.5 mm, medial–lateral −2.0 to −2.5 mm (right hemisphere). The dura mater is gently perforated to permit smooth needle passage.
4. Intracranial Cell Inoculation: LN229-luc cells are washed in sterile PBS and resuspended at 1×10⁵ cells in 3–5 µL of serum-free DMEM or PBS. A Hamilton syringe (26-gauge) mounted on a stereotactic frame is lowered through the burr hole to a depth of 2.5–3.0 mm below the dura mater (striatum target). The cell suspension is infused at a rate of 1 µL/min over 3–5 minutes, followed by a 2-minute dwell period before gradual needle retraction to minimize backflow.
5. Wound Closure and Postoperative Monitoring: The burr hole is sealed with bone wax, and the scalp is closed with surgical sutures or tissue adhesive. Mice recover on a heated pad until fully ambulatory. Postoperative analgesia (buprenorphine 0.05–0.1 mg/kg) is administered per IACUC guidelines. Body weight and neurologic signs are monitored at least three times weekly using a standardized grading scale.
6. Baseline and Longitudinal Bioluminescence Imaging: Beginning 3–5 days post-implantation, mice receive intraperitoneal D-luciferin (150 mg/kg in 100 µL PBS) and are imaged under isoflurane anesthesia using an IVIS Spectrum or equivalent system (acquisition: 30–60 s exposure, binning 4–8, f/stop 1.2). Regions of interest are drawn over the cranial cavity to quantify photon flux (photons/second), enabling weekly tracking of tumor engraftment, growth kinetics, and treatment response. Peak tumor signal is typically observed at 6–8 weeks.
7. Therapeutic Intervention and Response Assessment: Once tumors are established (confirmed by consistent BLI signal increase), mice are randomized into treatment and vehicle control cohorts. Therapeutic agents may be delivered systemically (intraperitoneal, intravenous, oral gavage) or via intratumoral injection. Response is evaluated through serial BLI, body weight trends, neurologic symptom scores, and Kaplan–Meier survival analysis. Optional small-animal MRI (T1-weighted with contrast, T2-weighted) provides anatomical correlation of tumor volume, edema, and necrosis.
8. Endpoint Analysis and Histopathological Validation: At study termination—defined by ethical endpoints (20% body weight loss, severe neurologic deficits, or predetermined time points)—mice are euthanized. Brains are excised intact, photographed, and processed for formalin-fixed paraffin-embedded sectioning. Coronal sections are stained with H&E for tumor morphology and margin assessment. Immunohistochemistry for GFAP, Ki-67, CD31, and cleaved caspase-3 quantifies tumor burden, proliferation, vascularity, and apoptosis. GFP or human-specific markers (e.g., anti-human mitochondria) confirm human tumor origin in xenograft tissue.

Fig 2. LN229-luc Orthotopic Mouse Model construction workflow.

Case Study-LN229-luc Orthotopic Mouse Model Development

In a representative preclinical engagement, the LN229-luc orthotopic model was utilized to evaluate the intracranial efficacy of a blood-brain barrier–penetrant PI3K inhibitor in combination with temozolomide against p53-mutant, PTEN-wild-type glioblastoma. Following stereotactic implantation, tumor engraftment was confirmed by weekly BLI, with photon flux increasing progressively over a 6-week observation window. Mice were randomized at Week 3 into monotherapy and combination arms, with combination-treated animals exhibiting a measurable reduction in bioluminescence signal intensity and delayed neurologic symptom progression relative to vehicle controls. Postmortem histopathology revealed diminished Ki-67 proliferation indices, reduced perivascular tumor cell infiltration, and increased cleaved caspase-3 staining in the combination cohort. These preclinical findings furnished supportive pharmacodynamic and efficacy data to inform subsequent formulation optimization and combination regimen design for advanced in vivo pharmacology studies.

Why Choose Alfa Cytology?

Engaging Alfa Cytology for your LN229-luc orthotopic glioblastoma program means partnering with a preclinical CRO that understands the nuances of human xenograft neuro-oncology models and the critical importance of longitudinal, quantitative readouts. Our defining advantages include:

• Validated luciferase-stable LN229 cell pools with documented in vitro and in vivo signal linearity, ensuring reliable quantitative bioluminescence tracking across the full disease course.
• Precision stereotactic neurosurgery expertise with optimized injection coordinates and flow rates that maximize engraftment consistency while minimizing perioperative morbidity in immunodeficient hosts.
• Integrated small-animal BLI and optional MRI capabilities for multimodal, longitudinal tumor monitoring—capturing both functional metabolic signal and anatomical tumor morphology, edema, and necrosis.
• Flexible study architectures supporting diverse therapeutic classes, including small-molecule kinase inhibitors, DNA-damaging agents, oncolytic viruses, antibody-drug conjugates, and nanoparticle-based delivery systems, with customizable dosing routes and schedules.
• Specialized neuropathology and molecular characterization services, including H&E margin analysis, perivascular invasion quantification, IHC panels (GFAP, Ki-67, CD31, caspase-3), and human-specific marker confirmation in xenograft tissue.
• Agile project management with dedicated scientific oversight, transparent milestone reporting, and adaptive protocol refinements to align with your evolving research priorities, regulatory timelines, and publication goals.

Contact Us

If your glioblastoma research program requires a translationally relevant, luciferase-enabled orthotopic model with diffuse infiltration kinetics and quantitative longitudinal readouts, Alfa Cytology is equipped to advance your preclinical objectives. Reach out to our scientific team to discuss your specific therapeutic hypothesis, review our LN229-luc model configurations and imaging protocols, and receive a customized study proposal tailored to your timeline and budget. Contact us today to collaborate with a specialized CRO dedicated to accelerating your brain cancer discovery pipeline.

For research use only. Not intended for any clinical use.